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Editorial on the Research Topic
Targeting Myeloid Cells to Fight Cancer
Refractory and relapsed cancer patients often develop resistance mechanisms associated with
an immunosuppressive tumor microenvironment (TME). Indeed, the TME is critically involved
not only in tumor growth, invasion and dissemination, but in immune editing and resistance
to different therapies both conventional and biological. Innate myeloid cells such as monocytes,
macrophages, neutrophils, and a diverse set of cells, sometime called myeloid derived suppressor
cells (MDSCs) may drive both local and systemic immunosuppression. These cells, however,
possess novel molecules and functions that could be targeted to fight against cancer making them
potential candidates for development of second-generation immunotherapy approaches. The aim
of this article collection is to provide a comprehensive overview of the different myeloid subsets in
the TME, and to describe recent developments and approaches targeting myeloid cells to enhance
anti-tumor immunity and the clinical efficacy of standard-of-care cancer drugs.
HETEROGENEITY OF MYELOID POPULATIONS
Neutrophils exhibit diverse and sometimes contradictory roles in the TME. The review by Jeong
et al. summarizes the regulation of neutrophils that determines the reciprocal dynamics between
them and tumor cells. This continuous interaction has expanded to a formidably complicated
network, including tumor types, tumor stages, subtypes of neutrophils, various signaling molecules
mediating crosstalk, and spatial-temporal interactions with other cell types. This ever-growing
complexity as reviewed by Jeong et al. has revealed how much more there is still to be learned
to be able to achieve effective and consistent therapeutic effects based upon targeting neutrophils.
This diversity is a point emphasized in the mini-review by Granot who suggests that simple binary
classifications are insufficient and that the context defines neutrophil types and functions. Mackey
et al. in their minireview address a particular aspect of the contextual regulation of neutrophils
in the TME, i.e. neutrophil maturation outside the bone marrow. This atypical maturation and
notably the promotion of immature neutrophils by tumors underlie many of the different responses
of neutrophils to cancer.
Similar to neutrophils, monocytes also show significant diversity in the TME. In their
review, Canè et al. support the notion of a “monocyte continuum” instead of classification
of stepwise differences between the different subtypes. They also maintain that monocytes are
more than precursors of macrophages and dendritic cells but also make a direct contribution
to cancer development themselves. An additional feature of this review is the summary of
current monocyte-targeting drugs and their mechanisms of actions. Along these lines, Mengos
et al. describes the documented clinical findings on a CD14+HLA-DRlo/neg monocyte population
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that has emerged as an important mediator of tumor-induced
immunosuppression. Different from MDSCs, these cells arise
from the regular circulating monocyte pool, which lose
HLA-DR expression and get deactivated after an acute or
chronic inflammatory trigger leading to immune paralysis. The
immunosuppressive monocytes can negatively affect responses
to immune checkpoint inhibitors and could be potentially used
as biomarkers to understand disparate responses to immune
activating drugs, in addition to their potential targeting to
increase immunotherapy responses.
SEEING IS BELIEVING
Cellular processes as analyzed by tissue sections at a certain
time point may be missed, impossible to obtain or even
misinterpreted. With new technologies, intravital optical
imaging is providing an unprecedented opportunity to look at
cancer cells and stromal cells in their native environment and
thus yields arguably the most reliable results in interpreting the
TME. Laviron et al. examine the pros and cons of intravital
imaging as compared to other approaches, such as cell sorting
and sequencing, and suggest that an integrative approach offers
the most valuable information.
COMPOUNDS AFFECTING MYELOID
FUNCTIONS IN THE TME
The mode of action of several FDA approved drugs such as
bisphosphonates, trabectedin, imatinib, and sunitinib has been
shown to involve the modulation of macrophage functions in
addition to their respective targets. Whether their macrophage
targeting effects are significantly contributing to drug efficacy
remains to be investigated. In their article Tanita et al. shed light
on the mode of action of bexarotene, a third-generation retinoid
that has been used for decades in the treatment of both early
and advanced cutaneous T-cell lymphomas (CTCL). The authors
show that bexarotene decreases CCL22 production by CD163+
macrophages in CTCL patients. Since CCL22 attracts CCR4+
lymphocytes, such as Tregs, Th2 cells, and also CTCL cells to
support tumor progression, this study proposes the potential of
targeting tumor associated macrophages (TAMs) in CTCL for
improved patient outcome (Tanita et al.)
Another interesting concept is reported by Willebrand et al.
where they studied the effect of high salt intake on the functional
modulation of MDSCs in the TME. Excess salt intake has
been previously shown to balance various innate and adaptive
immune cells toward a pro-inflammatory state, and believed to
be associated with several autoimmune disorders. Therefore, an
interesting question that the authors raised was whether high salt
conditions can promote anti-tumor immunity to inhibit tumor
growth? Surprisingly, the authors find that, while high-salt diet
altered T cell populations, the delay in tumor growth was largely
mediated by an impairment in MDSC suppressive functions
(Willebrand et al.) Thus, high salt-induced molecular changes
could be potentially utilized during immunotherapy.
POSSIBILITIES TO TARGET MYELOID
CELLS FOR IMPROVED CANCER CARE
As a general assumption, macrophages are mostly considered
to have an unfavorable role in cancer since they are effective
suppressors of anti-tumor immune responses and can contribute
to tumor progression in multiple ways. Tumor growth is often
compared to the wound healing process and is metaphorically
described as a “wound that does not heal.” Hua and Bergers
focus on two common components in these two intricately
related processes—blood vessels and immune cells. They explain
how tumor cells hijack the immunosuppressive and angiogenic
programs that occur during the resolution phase of wound
healing toward their own ends. The authors thus suggest
targeting both myeloid cells and angiogenesis to revert the
hijacked wound-healing process.
In a mini review Bercovici et al. discuss the plasticity of
macrophages and focus on macrophage regulated intratumoral
T cell migration and activation. The authors emphasize that
T cell focused treatments should be systematically replaced by
rational combination treatments stimulating both innate and
adaptive arms of the immune system. When appropriately
stimulated macrophages can effectively induce anti-tumor
responses in cooperation with T cells. To date, only a few
myeloid cell targeting strategies under clinical development
have yielded promising results and many have been terminated
due to toxicities. In their review Jahchan et al., indicate
the potential of targeting TAMs in cancer immunotherapy.
They make a persuasive case for such approaches through
the targeting of particular functions of TAMs or by altering
their differentiation to anti-tumoral responses either directly
or through the enhancement of immunotherapy. They also
provide an authoritative update of all current clinical trials using
these approaches.
As shown by this collection of articles, a tremendous diversity
of myeloid cells orchestrate tumor-stromal and stromal-stromal
interactions to regulate the final outcome of the disease.
Elucidation of the detailed mechanisms and systemic rational
evaluation of therapeutic targeting of these cells may be the key
to fighting cancer.
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